BR112023011689A2 - Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero - Google Patents

Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero

Info

Publication number
BR112023011689A2
BR112023011689A2 BR112023011689A BR112023011689A BR112023011689A2 BR 112023011689 A2 BR112023011689 A2 BR 112023011689A2 BR 112023011689 A BR112023011689 A BR 112023011689A BR 112023011689 A BR112023011689 A BR 112023011689A BR 112023011689 A2 BR112023011689 A2 BR 112023011689A2
Authority
BR
Brazil
Prior art keywords
antibody
obtaining
cells
antibodies
mammalian host
Prior art date
Application number
BR112023011689A
Other languages
English (en)
Portuguese (pt)
Inventor
David Suh
Ergang Shi
Gang Chen
Glen Farr
Robert Babb
Wen-Yi Lee
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112023011689A2 publication Critical patent/BR112023011689A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112023011689A 2020-12-23 2021-12-22 Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero BR112023011689A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063130044P 2020-12-23 2020-12-23
PCT/US2021/064769 WO2022140494A1 (en) 2020-12-23 2021-12-22 Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same

Publications (1)

Publication Number Publication Date
BR112023011689A2 true BR112023011689A2 (pt) 2023-10-31

Family

ID=82022075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023011689A BR112023011689A2 (pt) 2020-12-23 2021-12-22 Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero

Country Status (12)

Country Link
US (2) US12371487B2 (https=)
EP (1) EP4267608A1 (https=)
JP (1) JP2024501796A (https=)
KR (1) KR20230124594A (https=)
CN (1) CN116635413A (https=)
AU (1) AU2021409906A1 (https=)
BR (1) BR112023011689A2 (https=)
CA (1) CA3197426A1 (https=)
IL (1) IL303865A (https=)
MX (1) MX2023007583A (https=)
TW (1) TW202242114A (https=)
WO (1) WO2022140494A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116622754A (zh) * 2023-05-31 2023-08-22 南开大学 一种定点标记的跨膜蛋白纳米盘及其制备方法和应用
CN118027202B (zh) * 2024-03-14 2024-08-13 恺佧生物科技(上海)有限公司 结合slc13a5膜蛋白的抗体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
JP4939926B2 (ja) 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
WO2006058890A2 (en) * 2004-11-30 2006-06-08 Novo Nordisk A/S Method of producing antibodies
EP1910513B1 (en) * 2005-07-01 2016-08-10 John Schrader Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells.
EP2121007A1 (en) 2006-12-21 2009-11-25 Cytos Biotechnology AG Circular ccr5 peptide conjugates and uses thereof
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
MX353278B (es) 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
ES2676827T3 (es) 2012-06-01 2018-07-25 Heptares Therapeutics Limited Ensayos
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
EP2745834B1 (en) 2012-12-18 2016-09-28 Jens Frauenfeld Salipro particles
HK1218550A1 (zh) 2013-03-13 2017-02-24 Regeneron Pharmaceuticals, Inc. 常見輕鏈小鼠
EP4545567A3 (en) 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9850303B2 (en) 2013-03-15 2017-12-26 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to tetraspanin 8
ES2939555T3 (es) * 2014-11-14 2023-04-24 Regeneron Pharma Método para generar anticuerpos de alta afinidad
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
EP3284460A1 (en) 2016-08-19 2018-02-21 Salipro Biotech AG Saposin lipoprotein particles and libraries from crude membranes
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
US20210214719A1 (en) 2018-05-31 2021-07-15 Kangti Pte. Ltd. A yeast phenotypic screening method for isolation of functional antibodies against g-protein coupled receptors
US20210299070A1 (en) 2018-09-21 2021-09-30 Jnana Therapeutics, Inc. Methods of treating creatine transporter deficiency
US20210371403A1 (en) 2018-09-21 2021-12-02 Jnana Therapeutics, Inc. Small molecules targeting mutant mammalian proteins
WO2020061476A1 (en) 2018-09-21 2020-03-26 Jnana Therapeutics, Inc. Small molecules targeting mutant mammalian proteins

Also Published As

Publication number Publication date
US20220195038A1 (en) 2022-06-23
JP2024501796A (ja) 2024-01-16
EP4267608A1 (en) 2023-11-01
AU2021409906A9 (en) 2024-10-10
US20250313624A1 (en) 2025-10-09
AU2021409906A1 (en) 2023-06-15
MX2023007583A (es) 2023-07-07
WO2022140494A1 (en) 2022-06-30
KR20230124594A (ko) 2023-08-25
TW202242114A (zh) 2022-11-01
CN116635413A (zh) 2023-08-22
CA3197426A1 (en) 2022-06-30
IL303865A (en) 2023-08-01
US12371487B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
Davis et al. Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination
Kanduc From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry
Sielaff et al. Evaluation of FASP, SP3, and iST protocols for proteomic sample preparation in the low microgram range
Ecker et al. High-yield expression and purification of recombinant influenza virus proteins from stably-transfected mammalian cell lines
Lund et al. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers
Jensen Recent advances in antigen processing and presentation
Naryzhny et al. Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer
Nikolaus et al. Direct visualization of large and protein-free hemifusion diaphragms
Omenn et al. Progress identifying and analyzing the human proteome: 2021 metrics from the HUPO human proteome project
BR112023011689A2 (pt) Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero
BR112022023978A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno cd3 e usos dos mesmos
BR112015000505A2 (pt) método de analisar uma célula t geneticamente modificada para detectar um contaminante
CL2011000308A1 (es) Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune.
BRPI0911699B8 (pt) vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
BR112018012826A2 (pt) método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
BR112022011357A2 (pt) Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
Huang et al. Generating recombinant antibodies to membrane proteins through phage display
Unsworth et al. Studies on reticulin. I: Serological and immunohistological investigations of the occurrence of collagen type III, fibronectin and the non-collagenous glycoprotein of Pras and Glynn in reticulin
MX2021002125A (es) Receptores de celulas t restringidos a mr1 para inmunoterapia contra el cancer.
Mallis et al. Insights into biomechanical and proteomic characteristics of small diameter vascular grafts utilizing the human umbilical artery
JP2020510438A5 (https=)
Paik et al. Toward completion of the human proteome parts list: progress uncovering proteins that are missing or have unknown function and developing analytical methods
Buchli et al. Real-time measurement of in vitro peptide binding to soluble HLA-A* 0201 by fluorescence polarization
A. Wilson et al. Towards co-evolution of membrane proteins and metabolism
Georgakopoulos et al. An improved Fc function assay utilizing CMV antigen‐coated red blood cells generated with synthetic function–spacer–lipid constructs